NanoVibronix Reports 92% Revenue Growth and Net Income Turnaround in Q3 2025

NanoVibronix, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenues of approximately $722,000 for the third quarter, marking a 92% increase from $376,000 in the same period last year. For the nine months ended September 30, 2025, revenues totaled $2.241 million, a 6% increase compared to $2.114 million for the same period in 2024. The growth in revenue is attributed primarily to the addition of sales from ENvue products following the merger, although this was partially offset by a decline in sales of NanoVibronix products to its largest customer.

The company reported a net income of $510,000 for the third quarter, a significant turnaround from a net loss of $998,000 in the same quarter of 2024. However, for the nine-month period, the net loss increased to $5.333 million from $2.274 million in the prior year. This increase in loss was primarily driven by higher operating expenses, which rose significantly due to the inclusion of ENvue's operations post-merger. General and administrative expenses surged to $4.997 million for the nine months, up from $2.335 million, reflecting costs associated with the merger and increased operational activities.

In terms of operational metrics, the company reported a gross profit of $189,000 for the third quarter, up from $133,000 in the previous year, although the gross profit margin decreased to 26% from 35%. This decline was attributed to inventory write-offs and amortization costs related to technology. Research and development expenses decreased slightly to $221,000 from $249,000, while selling and marketing expenses saw a substantial increase to $812,000 from $181,000, largely due to the integration of ENvue's marketing efforts.

The merger with ENvue Medical Holdings, completed on February 14, 2025, has significantly impacted NanoVibronix's financial position. As of September 30, 2025, total assets increased to $54.383 million from $3.629 million at the end of 2024, primarily due to the consolidation of ENvue's assets. The company also reported an accumulated deficit of $76.858 million, raising concerns about its ability to continue as a going concern without additional funding. The company plans to address its liquidity needs through future equity offerings and strategic partnerships.

Looking ahead, NanoVibronix anticipates continued challenges in achieving profitability, with management indicating that future operations will depend on successful product commercialization and market conditions. The company is also navigating regulatory challenges, including the withdrawal of a 510(k) application for the PainShield MD Plus product, which it has decided to halt sales on. The ongoing geopolitical situation and economic conditions may further impact the company's operations and financial performance.